While deal volumes have slowed down in recent years, in line with the overall M&A activity, deals in the life sciences sector started to pick up again at the end of 2023 and continued in 2024.

Experts will discuss this M&A resurgence and its implications for early-stage deals, funding availability, business development prospects and deal pattern observations. What trends are observed in recent M&A deals? What is the current state of M&As and what patterns can be observed in deal structures? Are deals differing for mid-size companies? What are BD heads observing and how are they responding? What has been the impact of IRA on R&D and M&A strategies? What is the balance between acquisitions and partnerships in global strategies? Is the resurgence of M&A activity creating more opportunities or challenges for early-stage dealmaking? What therapeutic areas have been targeted by M&As and how does it affect biotech in a pre-deal environment? Are investors more likely to take risks earlier on as a result? What will large pharmas and investors be looking for in 2025?

Moderator: Claudia Andretta, Founder, Strategic Science & Business Advisor, Sichem Bio